Generic Name and Formulations:
Clindamycin (as HCl) 75mg+, 150mg+, 300mg; caps; +contains tartrazine.
Indications for CLEOCIN:
Serious susceptible infections where less toxic antibiotics are inappropriate, including respiratory, skin and soft tissue, septicemia, intraabdominal, female pelvic or genital; bone and joint (inj).
Take with full glass of water. Serious: 150–300mg every 6hrs. More severe: 300–450mg every 6hrs. Beta-hemolytic streptococcal infections: treat for at least 10 days.
Take with full glass of water. Serious: 8–16mg/kg per day. More severe: 16–20mg/kg per day. Divide into 3–4 equal doses. Beta-hemolytic streptococcal infections: treat for at least 10 days.
Not for treatment of meningitis. Discontinue if colitis occurs and treat. Permanently discontinue if severe hypersensitivity reactions occur. Allergy. Asthma (75mg, 150mg caps). GI disease (esp. colitis). Atopy. Monitor blood, renal, and hepatic function in long-term use and in children. IV: Gasping syndrome (neonates, infants). Elderly. Pregnancy. Nursing mothers: consider alternative drug.
May potentiate neuromuscular blocking agents; caution. May be potentiated by strong CYP3A4 inhibitors; monitor. May be antagonized by strong CYP3A4 inducers (eg, rifampicin); monitor. May antagonize erythromycin; avoid. Antiperistaltic agents may worsen colitis.
Pseudomembranous colitis, C. difficile-associated diarrhea, nausea, vomiting, abdominal pain, dysguesia, rash, pruritus, angioedema, anaphylaxis, jaundice, renal dysfunction, blood dyscrasias, polyarthritis, severe skin reactions (eg, toxic epidermal necrolysis, erythema multiforme, drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome).
Caps—100; Granules (100mL)—1; Inj (2mL, 4mL, 6mL vials)—25
Endocrinology Advisor Articles
- Long-Term Efficacy and Safety of Dapagliflozin for Type 1 Diabetes
- Measuring Time in Range During CGM May Be Useful Outcome Metric for Clinical Trials
- HbA1c Variability in General Population Increases Risk for Cardiovascular Events, All-Cause Mortality
- Safety and Effectiveness of the Most Common Bariatric Procedures Examined
- AHA, ADA Announce Joint Education Initiative to Reduce CVD Deaths in T2D
- High Circulating Prolactin Concentrations May Lower Risk for Type 2 Diabetes
- Online Tool Helps Patients With Advance Care Planning
- Dapagliflozin Lowers Heart Failure Hospitalization Rates in High-Risk Patients With Diabetes
- Direct-Acting Antiviral Therapy Reduced Risk for Incident T2D in Patients With Hepatitis C Infection
- Technological Breakthroughs in Medicine Move Physician-Patient Interactions From The Computer Screen Back to the Exam Room